Participating Companies

Genetron Health
Gen­etron Health of­fers full-cy­cle can­cer molec­u­lar di­ag­nos­tics prod­ucts and ser­vices from pre­ven­tion to treat­ment. Th­ese in­clude risk as­sess­ment, ear­ly screen­ing, molec­u­lar pathol­o­gy di­ag­no­sis, med­i­ca­tion gui­dance and prog­no­sis mon­i­tor­ing – spe­cial­ly catered to the needs of can­cer pa­tients, high-risk groups and the healthy pop­u­la­tion. [more in­for­ma­tion]
Immatics NV [IMTX] US$664 MM MCap
Im­mat­ics com­bines the dis­cov­ery of true tar­gets for can­cer im­munother­a­pies with the de­vel­op­ment of the right T cell re­cep­tors with the goal of en­abling a ro­bust and spe­cif­ic T cell re­sponse against th­ese tar­gets. We are com­mitt­ed to de­liv­er­ing the pow­er of T cells and to un­lock­ing new av­enues for pa­tients in their fight against can­cer. [more in­for­ma­tion]
Im­muno­core is a T cell re­cep­tor (TCR) com­pany, a glob­al biotech striv­ing to trans­form med­i­cal prac­tice in the most chal­leng­ing dis­ease ar­eas. This nov­el class of im­munother­a­py has the po­ten­tial to treat a broad spec­trum of dis­eas­es with high un­met med­i­cal need, not on­ly can­cers, but al­so in­fec­tious dis­eas­es and au­toim­mune dis­eas­es. [more in­for­ma­tion]
Lineage Cell Therapeutics [LCTX] US$141 MM MCap
Cell ther­a­py com­pany with 3 cl­ni­cal pro­grams 1) OpRe­gen, an RPE tran­s­plant ther­a­py in Ph1/2a de­vel­op­ment for the treat­ment of dry-AMD. 2) OPC1, an oli­go­den­dro­cyte pro­gen­i­tor cell ther­a­py for acute spi­nal cord in­juries with Or­phan and RMAT desig­na­tions. 3) VAC2, an al­lo­gene­ic can­cer im­munother­a­py of anti­gen-pre­sent­ing den­drit­ic cells cur­rent­ly in a Ph 1 for NS­CLC con­duct­ed by CRUK. [more in­for­ma­tion]
The com­pany's tech­nol­o­gy lev­er­ages the hu­man im­mune sys­tem to iden­ti­fy ful­ly hu­man mon­o­clo­n­al anti­bodies and dis­cov­er nov­el tar­gets that will lead to the de­vel­op­ment of anti­body-de­rived ther­a­peu­tics for the treat­ment of can­cer, pro­vid­ing a larg­er num­ber of can­cer pa­tients with the ben­e­fit of im­munother­a­py. [more in­for­ma­tion]
Strongbridge Biopharma [SBBP] US$138 MM MCap
Rare dis­eas­es; Keveyis for PPP revs ~21.7M for 2019 and $26 - $27M for 2020. Re­cor­lev for en­doge­nous Cush­ing's syn­drome Ph 3 pub­lished with to­p­line place­bo-con­trolled Ph 3 3Q20. [more in­for­ma­tion]
Sublimity Therapeutics
Eval­u­at­ing re­for­mu­lat­ed Cy­clos­porine as top­i­cal treat­ment in pa­tients with mod­er­ate to se­vere UC. Lead pro­gram in Phase 2b trial for mod­er­ate to se­vere Ul­cer­a­tive Coli­tis. Can­di­date is an oral calcineurin in­hibi­tor that de­liv­ers ther­a­peu­tic lev­els of the drug di­rect­ly to the in­flamed colon, while min­i­miz­ing side ef­fects typ­i­cal­ly as­so­ci­at­ed with sys­temic im­muno­mo­d­u­la­tors. [more in­for­ma­tion]
Targovax [TRVX:OS] NKr624 MM MCap
Pre­lim­i­nary Ph1b da­ta of OV ON­COS-102+che­mo in me­sothe­lio­ma re­sults: com­bo mPFS=8.4 mos. vs. con­trol mPFS=6.8 mos.; 1L pts mPFS-8.9 mos. Up­com­ing mile­s­tones: up­dat­ed clin­i­cal & im­mune da­ta in Ph2 me­sothe­lio­ma (1H20); pre­clin­i­cal da­ta on next-gen OV w/ dou­ble trans­genes (1H20); and clin­i­cal da­ta from Ph1 me­lano­ma study, part 2 with ex­tend­ed dos­ing (2H20). [more in­for­ma­tion]
Provider of so­lu­tions in­tend­ed for chal­leng­ing the boundary of in-sil­i­co. The com­pany's core of­fer­ings in­clude drug re­pur­pos­ing, in-sil­i­co tox­i­col­o­gy and ad­verse event pre­dic­tion, en­abling to un­cov­er or­gan-spe­cif­ic side ef­fect con­cerns with un­prece­dent­ed bi­o­log­i­cal ex­plain­a­bil­i­ty down to the path­way and pro­tein lev­el. [more in­for­ma­tion]
Zentalis [ZNTL] US$1,337 MM MCap
In ad­di­tion to its lead pro­gram, ZN-c5, an oral SERD for es­tro­gen re­cep­tor pos­i­tive, HER2-neg­a­tive breast can­cer, the Com­pany is de­vel­op­ing a broad pipe­line of on­col­o­gy can­di­dates, tar­get­ing ar­eas of ma­jor un­met med­i­cal need. [more in­for­ma­tion]